PTC Therapeutics, Inc.: Series E $50M

Posted in I - Series E, Q - 4Q09, R - NORTH EAST, X - CF, X - Hemophilia, X - Muscular Dystrophy, XX - NJ

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2009

Prosensa, BV: Series B $25.0M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Muscular Dystrophy, X - RNAi

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Feb

2007

Prosensa Holding BV: Series A $18M

Posted in I - Series A, R - INTERNATIONAL, X - Muscular Dystrophy

Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.

to top of page...